Rigel Pharmaceuticals (RIGL) Finished Goods (2018 - 2026)

Rigel Pharmaceuticals has reported Finished Goods for 9 years, with the latest figure at $4.1 million in Q1 2026.

• For the quarter ending Q1 2026, Finished Goods rose 9.05% year-over-year to $4.1 million; the trailing twelve-month figure through Mar 2026 stood at $4.1 million (up 9.05% YoY), and the FY2025 full-year result was $4.7 million, down 6.02% from the prior year.
• Finished Goods for Q1 2026 stood at $4.1 million, down from $4.7 million in the prior quarter.
• The five-year high for Finished Goods was $5.8 million in Q3 2024, with the low at $1.1 million in Q2 2022.
• Average Finished Goods over 5 years is $2.8 million, with a median of $2.0 million recorded in 2022.
• Year-over-year, Finished Goods soared 232.49% in 2024 and slumped 69.37% in 2025.
• Tracing RIGL's Finished Goods over 5 years: stood at $1.9 million in 2022, then declined by 20.8% to $1.5 million in 2023, then soared by 232.49% to $5.0 million in 2024, then dropped by 6.02% to $4.7 million in 2025, then declined by 13.05% to $4.1 million in 2026.
• The last three Finished Goods figures came in at $4.1 million (Q1 2026), $4.7 million (Q4 2025), and $1.8 million (Q3 2025), per Business Quant data.

Peer Comparison